Johannes Levin

Dr. Johannes Levin

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
GHGünter U. Höglinger
Günter U. Höglinger
GRGesine Respondek
Gesine Respondek
MSMaria Stamelou
Maria Stamelou
CKCarolin Kurz
Carolin Kurz
KJKeith A. Josephs
Keith A. Josephs
FGfor the Movement Disorder Society–endorsed PSP Study Group
for the Movement Disorder Society–endorsed PSP Study Group

21 January 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DNDominantly Inherited Alzheimer Network
Dominantly Inherited Alzheimer Network
OPOliver Preische
Oliver Preische
SSStephanie A. Schultz
Stephanie A. Schultz
AAAnja Apel
Anja Apel
JKJens Kuhle
Jens Kuhle
MJMathias Jucker
Mathias Jucker

11 March 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TNThe Dominantly Inherited Alzheimer Network
The Dominantly Inherited Alzheimer Network
NBNicolas R. Barthélemy
Nicolas R. Barthélemy
YLYan Li
Yan Li
NJNelly Joseph-Mathurin
Nelly Joseph-Mathurin
BGBrian A. Gordon
Brian A. Gordon
EMEric McDade
Eric McDade

1 March 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
BGBrian A Gordon
Brian A Gordon
TBTyler M Blazey
Tyler M Blazey
YSYi Su
Yi Su
AHAmrita Hari-Raj
Amrita Hari-Raj
ADAylin Dincer
Aylin Dincer
TBTammie L S Benzinger
Tammie L S Benzinger

10 January 2019 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
MSMarc Suárez-Calvet
Marc Suárez-Calvet
EMEstrella Morenas-Rodríguez
Estrella Morenas-Rodríguez
GKGernot Kleinberger
Gernot Kleinberger
KSKai Schlepckow
Kai Schlepckow
CHChristian Haass
Christian Haass
TREM2 is a transmembrane receptor that is predominantly expressed by microglia in the central nervous system. Rare variants in the TREM2 gene increase the risk for late-onset Alzheimer’s disease (AD). Soluble TREM2 (sTREM2) resulting from shedding of the TREM2 ectodomain can be detected in the cerebrospinal fluid (CSF) and is a surrogate measure of TREM2-mediated microglia function. CSF sTREM2 has been previously reported to increase at different clinical stages of AD, however, alterations in relation to Amyloid β-peptide (Aβ) deposition or additional pathological processes in the amyloid cascade (such as tau pathology or neurodegeneration) remain unclear. In the current cross-sectional study, we employed the biomarker-based classification framework recently proposed by the NIA-AA consensus guidelines, in combination with clinical staging, in order to examine the CSF sTREM2 alterations at early asymptomatic and symptomatic stages of AD. A cross-sectional study of 1027 participants of the Alzheimer’s Disease Imaging Initiative (ADNI) cohort, including 43 subjects carrying TREM2 rare genetic variants, was conducted to measure CSF sTREM2 using a previously validated enzyme-linked immunosorbent assay (ELISA). ADNI participants were classified following the A/T/N framework, which we implemented based on the CSF levels of Aβ1-42 (A), phosphorylated tau (T) and total tau as a marker of neurodegeneration (N), at different clinical stages defined by the clinical dementia rating (CDR) score. CSF sTREM2 differed between TREM2 variants, whereas the p.R47H variant had higher CSF sTREM2, p.L211P had lower CSF sTREM2 than non-carriers. We found that CSF sTREM2 increased in early symptomatic stages of late-onset AD but, unexpectedly, we observed decreased CSF sTREM2 levels at the earliest asymptomatic phase when only abnormal Aβ pathology (A+) but no tau pathology or neurodegeneration (TN-), is present. Aβ pathology (A) and tau pathology/neurodegeneration (TN) have differing associations with CSF sTREM2. While tau-related neurodegeneration is associated with an increase in CSF sTREM2, Aβ pathology in the absence of downstream tau-related neurodegeneration is associated with a decrease in CSF sTREM2.

19 April 2013 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
JWJens Wagner
Jens Wagner
SRSergey Ryazanov
Sergey Ryazanov
ALAndrei Leonov
Andrei Leonov
JLJohannes Levin
Johannes Levin
SSSong Shi
Song Shi
AGArmin Giese
Armin Giese
In neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and prion diseases, deposits of aggregated disease-specific proteins are found. Oligomeric aggregates are presumed to be the key neurotoxic agent. Here we describe the novel oligomer modulator anle138b [3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole], an aggregation inhibitor we developed based on a systematic high-throughput screening campaign combined with medicinal chemistry optimization. In vitro, anle138b blocked the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn), which is deposited in PD and other synucleinopathies such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Notably, anle138b strongly inhibited all prion strains tested including BSE-derived and human prions. Anle138b showed structure-dependent binding to pathological aggregates and strongly inhibited formation of pathological oligomers in vitro and in vivo both for prion protein and α-synuclein. Both in mouse models of prion disease and in three different PD mouse models, anle138b strongly inhibited oligomer accumulation, neuronal degeneration, and disease progression in vivo. Anle138b had no detectable toxicity at therapeutic doses and an excellent oral bioavailability and blood–brain-barrier penetration. Our findings indicate that oligomer modulators provide a new approach for disease-modifying therapy in these diseases, for which only symptomatic treatment is available so far. Moreover, our findings suggest that pathological oligomers in neurodegenerative diseases share structural features, although the main protein component is disease-specific, indicating that compounds such as anle138b that modulate oligomer formation by targeting structure-dependent epitopes can have a broad spectrum of activity in the treatment of different protein aggregation diseases.